Antibody-induced failure of botulinum toxin A therapy in cosmetic indications

Dermatologic Surgery

Volumn 36, Issue SUPPL. 4, 2010, Pages 2182-2187

  Dressler, Dirk ^a   Wohlfahrt, Kai ^a   Meyer Rogge, Ellen ^b   Wiest, Luitgard ^c   Bigalke, Hans ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BG KLINIKEN BERGMANNSTROST   (Germany)

^c Department of Private Practice ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; COSMETIC;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; DIAPHRAGM; DRUG FORMULATION; ESTHETICS; FEMALE; HUMAN; HYPERHIDROSIS; HYPERKINESIA; IMMUNE SYSTEM; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTIBODIES; BOTULINUM TOXINS, TYPE A; COSMETIC TECHNIQUES; FEMALE; HUMANS; MIDDLE AGED; NEUROMUSCULAR AGENTS; SKIN AGING; TREATMENT FAILURE;

EID: 78650126959     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2010.01710.x     Document Type: Article

References (15)

1. Truong D, Dressler D, Hallett M., Manual of Botulinum Toxin Therapy. Cambridge, UK: Cambridge University Press; 2009.
2. Dressler D., Botulinum toxin therapy failure: causes, evaluation procedures and management strategies. Eur J Neurol 1997; 4 (suppl 2): S67-70.
3. Borodic G., Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthal Plast Reconstr Surg 2006; 22: 239-40.
4. Lee SK., Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 2007; 33 (suppl 2): S105-10.
5. Goschel H, Wohlfarth K, Frevert J, et al,. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997; 147: 96-102.
6. Dressler D, Dirnberger G., Botulinum toxin therapy: risk factors for therapy failure. Mov Disord 2000; 15 (suppl 2): 51.
7. Dressler D, Benecke R., Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007; 29: 1761-8.
8. Jankovic J, Vuong KD, Ahsan J., Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186-8.
9. Â: complete antibody-induced therapy failure in hemifacial spasm. J Neurol 2004; 251: 360.
10. Â: complete antibody-induced therapy failure in cervical dystonia. J Neurol Neurosurg Psychiat 2007; 78: 108-9.
11. Â) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 2003; 250: 967-9.
12. Dressler D, Bigalke H., Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neuro. 2004; 52: 132-5. (Pubitemid 39551719)
13. Dressler D., Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 2000; 247: 809-10.
14. Dressler D., Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 2002; 48: 26-9.
15. Dressler D, Bigalke H., Botulinum toxin antibody titres after cessation of botulinum toxin therapy. Mov Disord 2002; 17: 170-3.